

Field Safety Notice: Overfilling of chamber during CliniMACS Prodigy LP-TCRα/β-19 System application

Bergisch Gladbach, 2024-03-12

Dear customer.

Miltenyi Biotec would like to draw your attention to the following problem that has been reported to the competent national authority:

Title: Overfilling of chamber during CliniMACS Prodigy LP-TCR α/β -19 System application

Product name and version(s) and UDI-DI:

CliniMACS Prodigy TS 310, CE (200-073-602) UDI-DI: 04049934003226 CliniMACS Prodigy Instrument (200-075-301) UDI 04049934135415 CliniMACS Prodigy LP-TCRα/β-19 System Application (part of the device)

Information:

In rare cases, during the usage of the CliniMACS Prodigy LP-TCR α/β -19 System an overfilling in the chamber of the CliniMACS Prodigy TS 310, CE was noticed.

These overfilling of chamber had led to chamber cracks resulting in the cellular product leaking into the chamber unit and/or collected in the CliniMACS Prodigy Supplementary bag of the CliniMACS Prodigy Instrument. This comprises the risk of impacting the sterility and a potential loss of a large volume of the cell product. This issue only occurred within application runs of the CliniMACS Prodigy LP-TCR α/β -19 System in a certain software module during the application. During the investigating and evaluation of these incidents, the module where the incidents happened has been identified and mitigating measures and risk reducing measures were formulated. These are described in the action section. To reduce the risk of such described events, and to inform the end users, this FSCA is required.

Actions:

Action by Miltenyi Biotec:

As mitigating measure an application software update for CliniMACS Prodigy LP-TCRα/β-19 System will be released. The application software update comprises different measures to further increase the safety of the process. Multiple checks will better ensure that fluid was actually removed from the chamber. The pump speed of some transfer steps towards the chamber is reduced to allow a more efficient pressure equalization and reduce the probability of chamber membranes getting wet. Additional pressure monitoring steps are included so an alarm is raised when there is a possibility of overfilling the chamber.

With the enabling of above mentioned control mechanisms the probability for overfilling of chambers is significantly reduced. After final design verification the software improvement will be rolled out to the market by April 2024.

Friedrich-Ebert-Str. 68 51429 Bergisch Gladbach Germany

Phone: +49 2204 8306-0 Fax: +49 2204 85197 E-mail: macsde@miltenyi.com

Registered Office: Bergisch Gladbach Commercial Register: AG Köln, HRA 34194 VAT No: DE 815 828 586

Directors: Stefan Miltenyi Dr. Boris Stoffel Norbert Hentschel Dr. Jürgen Schmitz Dr. Antoon Overstijns General Partner: Miltenyi Biotec Management B.V. Registered Office: Leiden (NL) Commercial Register: KvK No. 75270714

Kreissparkasse Köln | Sort Code: 370 502 99 Account Number: 334 000 378 BIC: COKSDE33XXX IBAN: DE56 3705 0299 0334 0003 78 Account Number: 4017 48 504
BIC: PBNKDEFFXXX
IBAN: DE92 3701 0050 0401 7485 04
Deutsche Bank | Sort Code: 370 700 60

Deutsche Bank | Sort Code: 370 700 6 Account Number: 6 512 909 00 BIC: DEUTDEDKXXX IBAN: DE47 3707 0060 0651 2909 00

Postbank Köln | Sort Code: 370 100 50

www.miltenyibiotec.com



Field Safety Notice: Overfilling of chamber during CliniMACS Prodigy LP-TCRα/β-19 System application

Bergisch Gladbach, 2024-03-12

Please get in contact with your technical support in order to request the software update.

Recommended actions for the user:

- 1) As from April 1st, 2024, request a software update for the CliniMACS Prodigy LP-TCRα/β-19 System from Miltenyi Biotec Technical Support (technicalsupport@miltenyi.com)
- 2) We strongly recommend the following safety measures for the period prior to an upgrade: :
 - i. Please check that the clamp of the CliniMACS Prodigy Supplementary Bag is open before starting the application. If a chamber leakage occurs, the Supplementary Bag is capable of collecting the leakage fluid. For proper handling of CliniMACS Prodigy Supplementary Bag please follow the respective instructions for use.
 - ii. During the run of CliniMACS Prodigy LP-TCRα/β-19 System the process should be observed, especially during the module concentrate bulk, as explained in the enclosed guide (Attachment 1).
 - Please handle all alarms given by the CliniMACS Prodigy carefully. Pay particular attention to pressure alerts that occur during transfer to chamber steps Call Miltenyi Biotec Technical Support for assistance.
 - iii. Ensure that during the planning process of a stem cell transplantation procedure involving clinical cell separation with the CliniMACS Prodigy LP-TCRα/β-19 System it is determined whether the risk described above needs additional clinical measures to be implemented.

Please forward this information to all persons who need to be informed.

Notwithstanding the situation described here, we would like to point out that healthcare professional should evaluate their transplant protocol and determine whether the risk described above needs additional clinical measures to be implemented.

It is important that you take the actions described in this safety information and acknowledge receipt of this letter. If the above information does not apply to your facility or the CliniMACS Prodigy has been transferred to another facility, please indicate this on the enclosed response form and forward this Safety Notice to the appropriate facility.

Thank you for consideration of the above measures in this matter and for your assistance. If you have any questions about this matter, please get in touch with our contact person: https://www.miltenyibiotec.com/support/technical-support.html

Yours sincerely, Miltenyi Biotec B.V. & Co. KG

Germany



Field Safety Notice: Overfilling of chamber during CliniMACS Prodigy LP-TCRα/β-19 System application

Bergisch Gladbach, 2024-03-12

Attachment 1 to ii: Guide to perform filling volume control

The operator is suggested to perform volume monitoring at the module concentrate bulk of the CliniMACS Prodigy LP-TCRα/β-19 CD19 depletion, especially in the following step.

Sequence at module:

The operator is suggested to perform volume monitoring at the module concentrate bulk of the LP-TCRab CD19 depletion, especially in the following step.

Sequence at module: After a fill-up step from bag at Valve 10 (V10), at Process (sub) step 10422 (Process (sub) steps are evident at the left lower corner of the GUI), the chamber is filled to the maximal volume specs. Following this the chamber centrifuges for 10 minutes at 2000rpm. After this 10 minutes, the Process (sub) step 10428 starts and marks the start of supernatant removal,

the valve mask open is the V13 V14 V17 V19 (valves are pressed in) while the peristaltic pump turns clockwise and the content is transported to the waste bag at V19. At the end of state 10428 the chamber has the following depicted filling status (Fig.1), which can be visually monitored.

If the chamber is not at this filling level when the (sub) step finishes, or any alerts are evident on the GUI screen, please pause the process and call the technical support. This will ensure the safety of further processing. If the filling status of the chamber is incorrect the processing can continue with the fill-up from V10 towards V17 (Chamber) and could overfill the chamber. Pressure alerts are possible. The monitoring of the chamber volume is recommended for the entire module concentrate bulk, the supernatant removal and fill-up will be performed cyclically until the bag at V10 is empty.




Fig.1, Moderately filled chamber. Chamber rotating, volume status safe for further fill-up steps. This picture shows the expected volume level at the end of state 10428 in concentrate bulk (blue arrow points to the liquid air border) module of the LP-TCRab CD19 depletion. If uncertain consult technical support.



Field Safety Notice: Overfilling of chamber during CliniMACS Prodigy LP-TCRα/ β -19 System application

Bergisch Gladbach, 2024-03-12

Page 1 of 1

Response form

Please send this response form to the following e-mail address as soon as possible, but no later than 30 days after receiving this letter: **globalcomplaints_mdr@miltenyi.com**

Thanks you for you	our cooperation.	
Customer / facility (names of all affected facilities)		
Address		
Name (contact person)		
Position		
Telephone number		
	☐ I confirm that I have rece ☐ The safety information d ☐ The device has been pa	
Name and address of the		ther facility:
Date / Signature	_	

Germany